DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Oncology Homepage

Isala and Elekta sign 15-year radiotherapy equipment partnership Will upgrade to state-of-the-art technology

Supplemental breast MR superior to ultrasound for screening breast cancer survivors But what about cost-effectiveness?

German researchers find sweet alternative to conventional MR contrast agents Imaging with glucose using 7T MR scanner

RaySearch inks OIS deal with the University of Wisconsin-Madison Planned launch in second half of 2017

Michigan cancer center is first to acquire MR linac radiation therapy system Henry Ford is installing the MRIdian Linac from ViewRay

Experts develop ultrasound scoring system guidelines for thyroid nodules May reduce unnecessary biopsies

PET/CT with Ga-68 finds prostate cancer sooner than conventional imaging Research from Australia presented at SNMMI

Researchers to undertake largest breast cancer clinical trial in Oklahoma Findings may have practice-changing implications

Precision-based medicine improves outcomes and drives down costs How oncologists are seeking ways to provide affordable and effective care

Siemens scores FDA approval for latest version of its syngo.via VB20 for MI software Equipped with a series of improved features

Courtesy of Dr. Neeta Pandit-Taskar
and Dr. Michael J. Morris

New PET imaging agent detects metastatic prostate cancer

by Lauren Dubinsky , Senior Reporter
Researchers at Memorial Sloan Kettering Cancer Center demonstrated that a new PET imaging agent can detect metastatic prostate cancer in regions that it has previously been difficult to spot. Results from the Phase 1 dose-escalation study of Zr-89-deferrioxamine-IAB2M were published in the December issue of The Journal of Nuclear Medicine.

With an estimated 1.1 million new cases and over 300,000 deaths annually from prostate cancer, it is the second most common cancer among men globally, according to the World Health Organization.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



X-ray, CT and MR are traditionally used to determine if prostate cancer has spread to other areas of the body, but it’s often a challenge to image. With this new molecular imaging approach, researchers have shown they can target both bone and soft tissue lesions.

The radiotracer combines a small amount of the radioactive material zirconium-89 with a fragment of an antibody called a minibody. The minibody has anti-prostate-specific membrane antigen qualities that cause it to attach to prostate cancer cells that traveled in the body.

PET then detects the particles that are emitted from the site and the resulting image shows the "hot spots" of PSMA overexpression. This method can detect prostate cancer cells that have metastasized to bone, which is the most difficult to find with standard approaches.

For the study, the researchers imaged 18 patients with new imaging agent, using PET/CT. They also conducted CT, MR, molecular bone and FDG-PET exams and then selected and biopsied the suspected disease sites.

They found the Zr-89-Df-IAB2M PET scans were positive in 17 of the patients with bone lesions found in nine and soft tissue disease found in 14.

The bone scans conducted with Tc-99m-methylene diphosphonate and FDG were positive for bone lesions in nine and six patients, respectively. CT and FDG scans were positive for soft tissue disease in 14 and 10 patients, respectively.

In two of the patients, a single site of disease in each patient was found only by Zr-89-Df-IAB2M. In total, the new agent detected 147 bone and 82 soft tissue lesions.

The researchers are hoping that once this approach is further developed, it will help to detect metastatic prostate cancer earlier and more accurately. They believe that after further validation, the agent may be used for targeted biopsies and even targeted radiotherapy.

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED